Biocon shares up 3% after US FDA nod for key cancer drugs

March 5, 2025

Biocon share price: Shares of Biocon Ltd rose 3% after Biocon Pharma received FDA approvals for cancer drugs Lenalidomide and Dasatinib, enhancing its US oncology market presence. The company also got tentative approval for Rivaroxaban. Despite recent stock declines, analysts suggest a potential 22% upside. Biocon’s Q3 profits dropped sharply due to a previous one-time gain.

More To Explore

Private sector banks expected to outperform amid easing liquidity conditions: Vinay Paharia

The consumption trend in India has weakened after almost three to four years of fairly strong consumption boost. So, we are positive long term, but

March 6, 2025

Indian markets to face cyclical consolidation, limited upside: Dhiraj Agarwal

Dhiraj Agarwal, MD of Ambit Investment Managers, notes potential for a near-term market bounce after months of decline, but warns of long-term challenges and moderate

March 6, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003